<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263767</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0435</org_study_id>
    <nct_id>NCT03263767</nct_id>
  </id_info>
  <brief_title>Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC</brief_title>
  <acronym>CYRIC</acronym>
  <official_title>Phase II Study Testing Prophylaxis Feasibility of Graft Versus Host Disease With Only High Dose Cyclophosphamide Post-transplantation for Patients Eligible to a Reduced-intensity Conditioning Regiment Prior to Allogenic Transplantation With a Compatible Familial or Non-familial Donor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute or chronic graft versus host disease is still the major complication of stem cells
      transplantation regarding morbidity and mortality.

      Recently, high dose cyclophosphamide utilization early after post-transplantation (day+ 3 and
      +4) not only for patients with HLA- haploidentical donor but also for patients with Human
      Leukocyte Antigen (HLA)-compatible donor, showed a great control of graft versus host disease
      after transplantation, allowing to consider stopping immunosuppressive treatment after the
      transplantation (Neoral=cyclosporine, cell-cept=mycophenolate mofetil). Indeed, this step has
      already been completed in myeloablative transplantation in adult patients.

      This approach could enable to avoid in the end several complications related to long term
      immunosuppressive drugs administration, while promoting quicker immunity recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BALTIMORE conditioning regiment will be used in this study with peripheral stem cell
      transplantation and fludarabine will be replaced by clofarabine for myeloid diseases (Acute
      Myeloide Leukemia, Myelodysplasia , myelofibrosis, Chronic Myeoloid Leukemia..) because of
      better antitumoral activity in this setting.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade 3 and 4 acute GVHD cortico-resistant</measure>
    <time_frame>100 days after transplantation</time_frame>
    <description>acute GVHD will be evaluated from International Mount Sinai criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>one year</time_frame>
    <description>number of days in aplasia (neutrophils&lt; 0.5 Giga/L and platelets&lt;20 G/l, number of transfusions (red blood and platelets)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>one year</time_frame>
    <description>chimerism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>one year, the last follow-up visit</time_frame>
    <description>blood and bone marrow analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>one year, the last follow-up visit</time_frame>
    <description>clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft and relapse free survival</measure>
    <time_frame>one year</time_frame>
    <description>time between Day O and relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic GVHD</measure>
    <time_frame>one year</time_frame>
    <description>chronic GVHD will be assessed with NCI criteria for evaluation of chronic GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non relapse mortality</measure>
    <time_frame>last follow-up visit</time_frame>
    <description>number of death unrelated to relapse or disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>1, 2, 3, 6 and 12 months after transplantation</time_frame>
    <description>proportion of full and mixed donor chimerism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>3, 6 and 12 months after transplantation</time_frame>
    <description>lymphocytes, monocytes, T4, T8, Natural Killer (NK), B cells rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of ghost factors associated with GVHD</measure>
    <time_frame>one year</time_frame>
    <description>Statistical Models to Identify Subjects with Ghost Prognosis Factors Nguyen JM. 2015</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of grade 3 and 4 after transplantation</measure>
    <time_frame>one year</time_frame>
    <description>time of occurring and frequency of grade 3 and grade 4 adverse events (CTCAE criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections frequency</measure>
    <time_frame>one year</time_frame>
    <description>time of occurring and frequency of viral (CytoMegalo Virus, Epstein Barr virus , BKV, adenovirus), bacterial, parasite and yeast infections, evaluated by Polymerase Chain Reaction (PCR), blood and urines cultures, biopsy if applicable</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>LYMPHOID HEMOPATHY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with lymphoid hemopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MYELOID HEMOPATHY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with myeloid hemopathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m² Intravenous 5 days from Day-6 to Day-2</description>
    <arm_group_label>LYMPHOID HEMOPATHY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>30 mg/m² Intravenous 5 days from Day-6 to Day-2</description>
    <arm_group_label>MYELOID HEMOPATHY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Full body irradiation</intervention_name>
    <description>2 grays at Day-1</description>
    <arm_group_label>LYMPHOID HEMOPATHY</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>14 mg/kg intravenous 2 days at Day - 6 and day -5</description>
    <arm_group_label>LYMPHOID HEMOPATHY</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg/kg intravenous 2 days at day +3 and day +4</description>
    <arm_group_label>LYMPHOID HEMOPATHY</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY</arm_group_label>
    <other_name>hight dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stem cell transplantation</intervention_name>
    <description>at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)</description>
    <arm_group_label>LYMPHOID HEMOPATHY</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY</arm_group_label>
    <other_name>graft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nuclear cells</intervention_name>
    <description>CD3+ cells if needed after transplantation</description>
    <arm_group_label>LYMPHOID HEMOPATHY</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY</arm_group_label>
    <other_name>Donor Lymphocytes Injection (DLI)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults ≤ 70 years old

          -  indication to stem cells transplantation with reduced-intensity conditioning regimen

          -  with a HLA-compatible familial 10/10 or non-familial donor

          -  Written signed informed consent form

          -  woman with childbearing potential under efficient control birth method during the
             trial and up to 12 months after cyclophosphamide stop

          -  men under efficient control birth method during the trial and up to 6 months after
             cyclophosphamide stop

          -  Negative serology to B and C hepatitis and to HIV

          -  Affiliated to social security

        Exclusion Criteria:

          -  - Eligible to myeloablative contioning regimen

          -  Other progressive malignancy disease or history of prior other malignancy in the last
             two years, with the exception of: curatively treated basal cell carcinoma or carcinoma
             in situ of the cervix

          -  Progressive mental illness disease

          -  Pregnant or Breastfeeding woman

          -  woman with childbearing potential without any efficient control birth

          -  Serious concomitant infection and not controlled

          -  Contra-indications to allogenic transplantation, especially:

               -  Cardiac: left ventricular ejection fraction &lt;45% assessed by transthoracic
                  echography or isotopic method (isotopic gamma-angiography)

               -  Respiratory: DLCO limiting fludarabine and busulfan use (DLCO&lt; 40% of theorical
                  value)

               -  Renal: creatinine clearance &lt; 60ml/min (MDRD method)

               -  Hepatic: transaminases &gt;5 Uper Per Normal (UPN) or bilirubin&gt; 2 UPN

          -  Contra-indications to cyclophosphamide:

               -  Urinary tract infections

               -  Acute urothelial toxicity due to cytotoxic chemotherapy or to radiotherapy

               -  Obstruction of urines flow

               -  Pre-existing hemorrhagic cystitis

               -  Yellow fever vaccination

          -  Cardiac condition preventing high dose cyclophosphamide utilization :

               -  New York Heart Association (NYHA) functional class II, III or IV

               -  Rhythmic, valvular or ischemic cardiomyopathy

          -  Minor

          -  Patient under guardianship or curatorship

          -  Patient under judicial protection

          -  Known or suspected hypersensitivity to cyclophosphamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrice CHEVALLIER, MD-PHD</last_name>
    <phone>+33 2 40 08 39 94</phone>
    <email>patrice.chevallier@chu-nantes.fr</email>
  </overall_contact>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral haemopoietic stem cell transplant</keyword>
  <keyword>High dose cyclophosphamide</keyword>
  <keyword>acute GVHD</keyword>
  <keyword>allogenic transplantation</keyword>
  <keyword>RIC (reduced-intensity conditioning)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

